Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Shire beats Street

Shire (LSE:SHP; SHPGY) posted second quarter non-GAAP earnings per ADS of $0.55, beating by $0.12 the Street's estimate of

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE